LGVN LGVNR - Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.